Abstract
Objective: To evaluate the risk of developing endocrine hyperactivity and carcinoma during a period of up to 5 yr in patients with apparently benign and non-functioning adrenal incidentalomas. Patients and methods: Thirty-two patients (mean age: 57.0±8.3 yr) were investigated in a prospective follow-up study for a median time of 24 months. Twentyeight patients had unilateral and 4 had bilateral masses. Initial avarage mass diameter was 17.47±6.60 mm. All patients were followed up yearly by physical examination, metabolic parameters, hormonal evaluation [morning cortisol after 3-mg dexamethasone suppression, urinary metanephrines, and upright aldosterone/plasma renin activity (PRA)]. Results: Among the clinical characteristics, 48% of patients were obese, 20% were hypertensive, 13 had Type 2 diabetes and impaired glucose tolerance. During follow-up period no significant change in the functional status was observed and no malignant transformation occured. Only 1 patient developed subclinical Cushing’s syndrome at the end of the 1st year and referred to surgery. Change in mass size was correlated with homeostasis model assessment of insulin resistance (p=0.002), upright aldosterone/PRA (p=0.041), cortisol after dexamethasone suppression (p=0.048) and 24-h urinary normetanephrine (p=0.005) levels. Gender, body mass index, glucose metabolism, and blood pressure were not found to be correlated with change in mass size and functional status. Conclusions: Due to the extremely low risk of developing malignancy during up to 5 yr of follow-up, conservative approach for the management of adrenal incidentalomas is thought to be appropriate. However, possibility of evolution to hormonal hypersecretion makes long-term follow-up of 2-to-5 yr seems to be obligatory.
Similar content being viewed by others
References
Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR The clinically inapperant adrenal mass: update in diagnosis and management. Endocr Rev 2004, 25: 309–40.
Libè R, Dall’Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B. Long-term follow-up study of patients with adrenal incidentalomas. Europen J of Endocrinol 2002, 147: 489–94.
Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995, 16: 460–84.
Gross MD, Shapiro B. Clinically silent adrenal masses. J Clinic Endocrinol Metab 1993, 77: 885–8.
Bülow B, Jansson S, Juhlin C. Adrenal incidentaloma-follow-up results from a Swedish prospective study. Eur J Endocrinol 2006, 154: 419–23.
Grossrubatscher E, Vignati F, Possa M, Lohi P. The natural history of incidentally discovered adrenocortical adenomas: A retrospective evaluation. J Endocrinol Invest 2001, 24: 846–55.
Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M. Risk factors and long-term follow-up of adrenal incidentalomas. J Clinic Endocrinol Metab 1999, 84: 520–6.
Reincke M Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am 2000, 29: 43–56.
Linos DA. Management approaches to adrenal incidentalomas(adrenalomas). A view from Athens, Greece. Endocrinol Metab Clin North Am 2000, 29: 141–57.
Vilar L, Freitas Mda C, Canadas V, et al. Adrenal incidentalomas: Diagnostic evaluation and long-term follow-up. Endocr Pract 2008, 14: 269–78.
Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapperant adrenal mass (“incidentaloma”). Ann Intern Med 2003, 138: 424–9.
Mantero F, Arnaldi G 2000 Management approaches to adrenal incidentalomas. Endocrinol Metab Clin North Am 29: 107–25.
Sirén J, Tervahartiala P, Sivula A, Haapiainen R. Natural course of adrenal incidentalomas: seven-year follow-up study. World J Surg 2000, 24: 579–82.
Sirén JE, Haapiainen RK, Huikuri KT, Sivula AH. Incidentalomas of the adrenal gland: 36 operated patients and review of the literature. World J Surg 1993, 17: 634–9.
Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. J Clinic Endocrinol Metab 2000, 85: 637–44.
Bernini GP, Moretti A, Oriandini C, Bardini M, Taurino C, Salvetti A. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. British J Cancer 2005, 92: 1104–9.
Jockenhövel F, Kuck W, Hauffa B, et al. Conservative and surgical management of incidentally discovered adrenal tumors. J Endocrinol Invest 1992, 15: 331–7.
Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevelance and natural history of adrenal incidentalomas. Eur J Endocrinol 2003, 149: 273–85.
Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: Clinical and biochemical features. J Clin Endocrinol Metab 2000, 85: 1440–8.
Valli N, Catargi B, Ronci N, et al Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Europen J Endocrinol 2001, 144: 401–8.
Eldeiry LS, Garber JR Adrenal incidentalomas, 2003 to 2005: Experience after publication of the National Institutes of Health Consensus Statement. Endocr Pract 2008, 14: 279–84.
Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: Diagnostic uncertanities and clinical implications. J Endocrinol Invest 2006, 29: 471–82.
Garrapa G, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing’s syndrome. J Clinic Endocrinol Metab 2001, 86: 5301–6.
Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clinic Endocrinol Metab 2002, 87: 998–1003.
Reincke M, Fassnacht M, Väth S, Mora P, Allolio B. Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocrine Research 1996, 22: 757–61.
Singh PK, Bush HN. Adrenal insidentaloma: evaluation and management. J Clin Pathol 2008, 61: 1168–73.
Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s Syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93: 1526–40.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yılmaz, H., Tütüncü, N.B. & Şahin, M. Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas. J Endocrinol Invest 32, 913–916 (2009). https://doi.org/10.1007/BF03345772
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345772